Pirfenidone Tablet, Film Coated
Product Images NDC 0904-7397

This text describes a medication called Pirfenidone in tablet form, with each tablet containing 267 mg of the active ingredient. The usual dosage information can be found in the package insert. The tablets are to be stored at a temperature between 15°C to 30°C. The manufacturer is MSN Pharmaceuticals Inc., located in Piscataway, NJ, while the distributor is MAJOR PHARMACEUTICALS in Indianapolis, IN. The product is indicated for prescription use only.*

This is a description of a pack of Pirfenidone Tablets containing 267 mg of pirfenidone each. The package includes GTIN, SIN, EXP, and LOT details. The tablets should be stored at 25°C with excursions permitted to 15°C - 30°C, according to USP Controlled Room Temperature guidelines. It is critical to keep the tablets out of reach of children. The tablets come in a film-coated form, and the usual dosage information can be found in the package insert. The tablets are manufactured by MSN Pharmaceuticals Inc. and distributed by MAJOR PHARMACEUTICALS. It seems like there is also information related to an unvarnished area on the packaging that measures 4.72 x 1.7 inches (120 x 45 mm).*

This is a text containing information about a pharmaceutical product with the NDC number 0904-7398-89. It is a film-coated tablet containing pirfenidone with a dosage of 801 mg. The user is advised to refer to the package insert for dosage instructions and administration information. The tablets should be stored at 25°C with excursions permitted to 15-30°C, in a controlled room temperature environment. The manufacturer is MSN Pharmaceuticals Inc. based in Piscataway, NJ, and the product is distributed by Major Pharmaceuticals in Indianapolis, IN. For more information, visit www.majorpharmaceuticals.com.*

This document appears to describe a research study or clinical trial evaluating the effect of Pirfenidone versus a Placebo on lung function over 52 weeks. The data includes percentages, numeric values indicating changes in lung function, and categories such as worsening (decrease in %FVC) and no decline (increase in %FVC). The study may involve a total of 555 participants (278 in the Pirfenidone group and 277 in the Placebo group). The document also likely discusses the absolute change in %FVC from baseline to Week 52.*

This is a statistical comparison between Pirfenidone and Placebo in a study with 623 and 624 patients respectively. The percentage of patients alive was evaluated over the weeks, showing a Hazard Ratio (HR) with a confidence interval (CI) of 0.75 (0.51 - 1.11). The graph displays the survival rates over time for both groups.*